Literature DB >> 24839496

Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate.

Yasukiyo Murakami1, Ken-Ichi Tabata1, Atsushi Sugita1, Kohei Mochizuki1, Ryota Maeyama1, Miyoko Okazaki2, Morihiro Nishi1, Kazumasa Matsumoto1, Tetsuo Fujita1, Takefumi Satoh1, Shi-Xu Jiang3, Makoto Saegusa3, Masatsugu Iwamura1.   

Abstract

A 22-year-old man was referred to our hospital with macroscopic hematuria and consistent anal pain. Magnetic resonance imaging revealed an enlarged prostate tumour invading the bladder and rectum. A biopsy revealed an unclassified spindle cell sarcoma. Subsequently, radical cystoprostatectomy and resection of the rectum were performed. A histopathological examination revealed a prostatic malignant phyllodes tumour with a negative surgical margin. However, a local recurrence was identified 2 months after surgery. Induction therapy included 4 cycles of systemic chemotherapy comprising etoposide with ifosfamide and cisplatin. Although a partial response was observed at the local site, lung metastasis developed. Second-line chemotherapy with ifosfamide and doxorubicin with radiotherapy to the pelvis was administered and led to complete regression; however, its efficacy was transient. Although additional chemotherapy was administered, the patient eventually died due to the rapidly growing, recurrent tumour.

Entities:  

Year:  2014        PMID: 24839496      PMCID: PMC4001657          DOI: 10.5489/cuaj.1648

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  9 in total

1.  Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung.

Authors:  Kwok Chi Lam; Winnie Yeo
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

2.  Successful therapy of a malignant phyllodes tumor of the prostate after postoperative local failure.

Authors:  Mizuaki Sakura; Tetsurou Tsukamoto; Junji Yonese; Yuichi Ishikawa; Nozomu Aoki; Iwao Fukui
Journal:  Urology       Date:  2006-04-05       Impact factor: 2.649

3.  Phyllodes tumor of the prostate.

Authors:  Tomomi Fujii; Keiji Shimada; Nobumichi Tanaka; Kiyohide Fujimoto; Noboru Konishi
Journal:  Pathol Int       Date:  2012-03       Impact factor: 2.534

4.  In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

Authors:  D S Alberts; P T Fanta; K L Running; L P Adair; D J Garcia; R Liu-Stevens; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

5.  Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.

Authors:  Flavia Morales-Vásquez; Ana Maria Gonzalez-Angulo; Kristine Broglio; Horacio N Lopez-Basave; Dolores Gallardo; Gabriel N Hortobagyi; Jaime G De La Garza
Journal:  Breast J       Date:  2007 Nov-Dec       Impact factor: 2.431

6.  Phyllodes tumor of the prostate: long-term followup study of 23 cases.

Authors:  David G Bostwick; Deloar Hossain; Junqi Qian; Roxann M Neumann; Ping Yang; Robert H Young; P Anthony di Sant'agnese; Edward C Jones
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

7.  Malignant phyllodes tumor of the prostate. A case report with immunohistochemical and ultrastructural studies.

Authors:  J F Young; P E Jensen; C A Wiley
Journal:  Arch Pathol Lab Med       Date:  1992-03       Impact factor: 5.534

8.  Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.

Authors:  Norio Nonomura; Daizo Oka; Kazuo Nishimura; Masashi Nakayama; Hitoshi Inoue; Yoichi Mizutani; Tsuneharu Miki; Akihiko Okuyama
Journal:  Int J Urol       Date:  2007-06       Impact factor: 3.369

9.  Case report: Malignant phyllodes tumor of prostate.

Authors:  Vivek Agrawal; Deborshi Sharma; Neelam Wadhwa
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

  9 in total
  2 in total

1.  Benefits from standalone durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report.

Authors:  Lili Wang; Lei Wang; Dingkun Hou; Shiqiang Dong; Aixiang Wang; Haitao Wang
Journal:  Transl Androl Urol       Date:  2021-11

2.  Primary prostate sarcoma: how to manage following diagnosis at transurethral resection.

Authors:  Natalie Hicks; Pratik M S Gurung; Nayneeta Deshmukh; Ikechukwu Apakama; Prashant Patel
Journal:  J Surg Case Rep       Date:  2016-05-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.